Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Colorectal Neoplasms 3Hematologic Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms 1Melanoma 1MCRC 1Lymphopenia 1Locally Advanced Rectal Cancer 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Capecitabine 20Oxaliplatin 13Irinotecan 8spartalizumab 6tislelizumab 4Radiation 4Neoadjuvant Therapy 4Immune Checkpoint Inhibitors 4Fluorouracil 4toripalimab 3sintilimab 2camrelizumab 2Radiotherapy 2Leucovorin 2Celecoxib 2veliparib 1peposertib 1nimotuzumab 1irinotecan sucrosofate 1XELOX 1Thymalfasin 1Radiotherapy, Intensity-Modulated 1Injections 1HMPL-013 1Folfox protocol 1Diathermy 1Combined Modality Therapy 1Chemoradiotherapy 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Rectal Cancer × Thymalfasin × Clear all
NCT06056804 2025-04-02

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Beijing Friendship Hospital

Phase 2 Active not recruiting
20 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡